These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 28452151

  • 21. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S, Gambino G, Cristiano LM, Pierce GF, Allen G.
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [Abstract] [Full Text] [Related]

  • 22. Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products.
    Tegenge MA, Yang H, Forshee RA.
    Haemophilia; 2017 Sep; 23(5):705-711. PubMed ID: 28543946
    [Abstract] [Full Text] [Related]

  • 23. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.
    Hampton K, Chowdary P, Dunkley S, Ehrenforth S, Jacobsen L, Neff A, Santagostino E, Sathar J, Takedani H, Takemoto CM, Négrier C.
    Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862
    [Abstract] [Full Text] [Related]

  • 24. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, Key NS, Portron A, Schmitt C, Podolak-Dawidziak M, Selak Bienz N, Hermans C, Campinha-Bacote A, Kiialainen A, Peerlinck K, Levy GG, Jiménez-Yuste V.
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [Abstract] [Full Text] [Related]

  • 25. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
    Meunier S, Alamelu J, Ehrenforth S, Hanabusa H, Abdul Karim F, Kavakli K, Khodaie M, Staber J, Stasyshyn O, Yee DL, Rageliene L.
    Thromb Haemost; 2017 Aug 30; 117(9):1705-1713. PubMed ID: 28692108
    [Abstract] [Full Text] [Related]

  • 26. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.
    Cheng X, Li P, Chen Z, Zhang N, Zhen Y, Zhao L, Wang X, Wu R.
    Haemophilia; 2018 Jan 30; 24(1):120-125. PubMed ID: 29194866
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The first recombinant FVIII produced in human cells--an update on its clinical development programme.
    Valentino LA, Negrier C, Kohla G, Tiede A, Liesner R, Hart D, Knaub S.
    Haemophilia; 2014 Jan 30; 20 Suppl 1():1-9. PubMed ID: 24330348
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A.
    Huang K, Zhen Y, Li G, Wu X, Chen Z, Wu R.
    Haemophilia; 2021 Jul 30; 27(4):e450-e457. PubMed ID: 34015176
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
    Zhao Y, Hu Y, Jin J, Zhao X, Wang X, Wu R, Wu D, Yang R, Yang F, Hu Q, Wang J, Fang H, Engl W.
    Clin Appl Thromb Hemost; 2021 Jul 30; 27():1076029621989811. PubMed ID: 33587652
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.
    Simpson ML, Desai V, Maro GS, Yan S.
    J Manag Care Spec Pharm; 2020 Apr 30; 26(4):504-512. PubMed ID: 32020842
    [Abstract] [Full Text] [Related]

  • 36. PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A.
    Santagostino E, Kenet G, Fischer K, Biss T, Ahuja S, Steele M.
    Haemophilia; 2020 May 30; 26(3):e55-e65. PubMed ID: 32212300
    [Abstract] [Full Text] [Related]

  • 37. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
    Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML.
    Thromb Haemost; 2021 Aug 30; 121(8):1079-1086. PubMed ID: 33296943
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A.
    Megías-Vericat JE, Bonanad S, Haya S, Cid AR, Marqués MR, Monte E, Pérez-Alenda S, Bosch P, Querol F, Poveda JL.
    Thromb Res; 2019 Feb 30; 174():151-162. PubMed ID: 30634166
    [Abstract] [Full Text] [Related]

  • 40. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting.
    Kruse-Jarres R, Oldenburg J, Santagostino E, Shima M, Kempton CL, Kessler CM, Lehle M, Chebon S, Selak Bienz N, Asikanius E, Mahlangu J.
    Haemophilia; 2019 Mar 30; 25(2):213-220. PubMed ID: 30724422
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.